{"id":61933,"date":"2024-11-23T00:04:37","date_gmt":"2024-11-23T00:04:37","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/11\/23\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/"},"modified":"2024-11-23T00:04:37","modified_gmt":"2024-11-23T00:04:37","slug":"boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/","title":{"rendered":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime<sup>1<\/sup><\/i><\/li>\n<li><i>Previous studies have shown that\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0could help\u00a0improve\u00a0the\u00a0survival\u00a0time\u00a0and quality\u00a0of\u00a0life\u00a0for\u00a0dogs\u00a0with\u00a0congestive\u00a0heart\u00a0failure\u00a0due\u00a0to\u00a0myxomatous\u00a0mitral\u00a0valve\u00a0disease (MMVD) or dilated cardiomyopathy (DCM)<sup>2,3<\/sup><\/i><\/li>\n<li><i>The new\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution\u00a0offers\u00a0pet\u00a0owners\u00a0a\u00a0convenient,\u00a0liquid\u00a0oral\u00a0treatment\u00a0option\u00a0for those dogs that prefer a liquid<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DULUTH, Ga<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 23, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Boehringer Ingelheim,\u00a0a\u00a0global leader\u00a0in\u00a0animal health, launched\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution, the first\u00a0oral\u00a0solution approved\u00a0by the\u00a0U.S.\u00a0Food and Drug Administration\u00a0(FDA) for\u00a0the\u00a0management\u00a0of congestive\u00a0heart\u00a0failure\u00a0(CHF)\u00a0in dogs\u00a0due to MMVD or DCM.<\/p>\n<p>Unfortunately, heart disease in dogs is common, affecting approximately 10 percent of dogs in their lifetime.<i><sup>1<\/sup> <\/i>Most frequently, dogs are affected by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM), both which may progress to CHF, characterized by the inability of the heart to effectively pump blood throughout the body.<\/p>\n<p>Now\u00a0pet\u00a0owners\u00a0have\u00a0a\u00a0convenient,\u00a0new\u00a0management\u00a0option\u00a0to\u00a0support\u00a0the\u00a0hearts\u00a0of\u00a0dogs\u00a0with CHF:\u00a0a\u00a0liquid\u00a0version of\u00a0VETMEDIN<sup>\u00ae<\/sup>,\u00a0one\u00a0of\u00a0the\u00a0leading\u00a0canine cardiology\u00a0medications\u00a0in\u00a0the\u00a0world. Previous studies have shown that VETMEDIN<sup>\u00ae<\/sup> could help increase the survival time and quality of life\u00a0in\u00a0dogs\u00a0due\u00a0to\u00a0MMVD\u00a0or\u00a0DCM.<sup>2,3<\/sup><\/p>\n<p><b>IMPORTANT SAFETY\u00a0INFORMATION: VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution (pimobendan oral solution) and\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0(pimobendan)\u00a0Chewable\u00a0Tablets<\/b><\/p>\n<p>VETMEDIN\u00ae Solution (pimobendan oral solution) and VETMEDIN\u00ae (pimobendan) Chewable Tablets are\u00a0for\u00a0use\u00a0in dogs\u00a0with clinical\u00a0evidence\u00a0of\u00a0heart\u00a0failure\u00a0only\u00a0and\u00a0should\u00a0not\u00a0be\u00a0given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information,\u00a0see\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=974748614&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FVetmedinSolutionPI_2024.pdf&amp;a=full%C2%A0prescribing%C2%A0information%C2%A0for%C2%A0Vetmedin%C2%A0Solution\" target=\"_blank\" rel=\"nofollow\">full\u00a0prescribing\u00a0information\u00a0for\u00a0Vetmedin\u00a0Solution<\/a><\/u>\u00a0or\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3387904468&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin_PI.pdf&amp;a=see%C2%A0full%C2%A0prescribing\" target=\"_blank\" rel=\"nofollow\">see\u00a0full\u00a0prescribing<\/a><\/u>\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=2962480092&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin_PI.pdf&amp;a=information%C2%A0for%C2%A0Vetmedin+Chewable%C2%A0Tablets\" target=\"_blank\" rel=\"nofollow\">information\u00a0for\u00a0Vetmedin Chewable\u00a0Tablets<\/a><\/u>\u00a0or\u00a0visit\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3681435076&amp;u=https%3A%2F%2Fbi-animalhealth.com%2Fpets%2Fcanine%2Fproducts%2Ftherapeutics%2Fvetmedin&amp;a=Vetmedinclinic.com\" target=\"_blank\" rel=\"nofollow\">Vetmedinclinic.com<\/a><\/u><\/p>\n<p>&#8220;We continue to\u00a0deliver\u00a0new\u00a0innovations rooted\u00a0in\u00a0robust\u00a0clinical\u00a0evidence to help\u00a0more\u00a0pets,&#8221;\u00a0said Daniel\u00a0Watkins,\u00a0VP\u00a0US\u00a0Pet\u00a0Business,\u00a0Boehringer\u00a0Ingelheim.\u00a0&#8220;We\u00a0know\u00a0some\u00a0dogs\u00a0and\u00a0pet\u00a0owners may\u00a0prefer\u00a0a\u00a0liquid\u00a0medication,\u00a0especially\u00a0for\u00a0smaller dogs.\u00a0With\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution,\u00a0an\u00a0easy-to- use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives.&#8221;<\/p>\n<p>VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution,\u00a0now\u00a0available\u00a0in\u00a0the\u00a0U.S.,\u00a0provides\u00a0the\u00a0same\u00a0dual\u00a0mode\u00a0of\u00a0action\u00a0as VETMEDIN<sup>\u00ae<\/sup> Chewable Tablets. The flavorless, twice-daily liquid oral solution should be administered directly into the dog&#8217;s mouth.<\/p>\n<p>Since\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0was\u00a0first\u00a0introduced\u00a025\u00a0years\u00a0ago,\u00a0dogs\u00a0and\u00a0their\u00a0owners\u00a0around\u00a0the\u00a0world\u00a0have enjoyed more than 1 million years of additional life to love.<sup>4<\/sup> VETMEDIN<sup>\u00ae<\/sup>\u00a0Chewable Tablets are approved\u00a0for\u00a0the\u00a0management\u00a0of\u00a0the\u00a0signs\u00a0of\u00a0mild, moderate,\u00a0or\u00a0severe CHF\u00a0in\u00a0dogs\u00a0due\u00a0to\u00a0clinical MMVD or DCM. VETMEDIN<sup>\u00ae<\/sup> Chewable Tablets are indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.<\/p>\n<p>Boehringer Ingelheim also offers VETMEDIN<sup>\u00ae<\/sup>-CA1 (pimobendan), which has FDA conditional approval\u00a0for\u00a0use\u00a0in\u00a0dogs\u00a0with\u00a0Stage\u00a0B2\u00a0preclinical\u00a0MMVD\u00a0\u2013\u00a0which\u00a0may\u00a0enable\u00a0a\u00a0delay\u00a0in\u00a0the\u00a0onset of heart failure symptoms.<\/p>\n<p>For\u00a0more\u00a0information,\u00a0visit\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=2054423097&amp;u=http%3A%2F%2Fwww.boehringer-ingelheim.com%2Fanimal-health&amp;a=www.boehringer-ingelheim.com%2Fanimal-health.\" target=\"_blank\" rel=\"nofollow\">www.boehringer-ingelheim.com\/animal-health<u>.<\/u><\/a><\/u><\/p>\n<p><b>IMPORTANT SAFETY\u00a0INFORMATION: VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution (pimobendan oral solution) and\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0(pimobendan)\u00a0Chewable\u00a0Tablets<\/b><\/p>\n<p>VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution\u00a0and\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0Chewable Tablets\u00a0are\u00a0for\u00a0use\u00a0in\u00a0dogs\u00a0with\u00a0clinical\u00a0evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea,\u00a0dyspnea,\u00a0azotemia,\u00a0weakness,\u00a0and\u00a0ataxia.\u00a0VETMEDIN<sup>\u00ae<\/sup>\u00a0Solution\u00a0and\u00a0VETMEDIN<sup>\u00ae<\/sup> Chewable Tablets should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any\u00a0other\u00a0clinical\u00a0condition\u00a0where\u00a0an\u00a0augmentation\u00a0of\u00a0cardiac\u00a0output\u00a0is\u00a0inappropriate\u00a0for functional or anatomical reasons. For more information, see <u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=963318711&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FVetmedinSolutionPI_2024.pdf&amp;a=full+prescribing+information\" target=\"_blank\" rel=\"nofollow\">full prescribing information<\/a><\/u><\/p>\n<p>or\u00a0visit\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3681435076&amp;u=https%3A%2F%2Fbi-animalhealth.com%2Fpets%2Fcanine%2Fproducts%2Ftherapeutics%2Fvetmedin&amp;a=Vetmedinclinic.com\" target=\"_blank\" rel=\"nofollow\">Vetmedinclinic.com<\/a><\/u><\/p>\n<p><b>IMPORTANT\u00a0SAFETY\u00a0INFORMATION:\u00a0VETMEDIN<sup>\u00ae<\/sup>-CA1\u00a0(pimobendan)<\/b><\/p>\n<p><b>VETMEDIN<sup>\u00ae<\/sup>-CA1\u00a0(pimobendan)\u00a0is\u00a0for use\u00a0only\u00a0in\u00a0dogs\u00a0with\u00a0preclinical\u00a0MMVD\u00a0that\u00a0have\u00a0a moderate\u00a0or loud\u00a0mitral\u00a0murmur\u00a0due to\u00a0mitral\u00a0regurgitation\u00a0and cardiomegaly\u00a0(Stage\u00a0B2\u00a0MMVD, 2019\u00a0ACVIM\u00a0Consensus\u00a0Statement1).\u00a0Is a\u00a0violation\u00a0of\u00a0Federal\u00a0law\u00a0to use\u00a0this\u00a0product\u00a0other\u00a0than as\u00a0directed\u00a0in\u00a0the labeling.\u00a0VETMEDIN-CA1\u00a0is\u00a0conditionally\u00a0approved\u00a0by FDA\u00a0pending\u00a0a\u00a0full demonstration\u00a0of\u00a0effectiveness\u00a0under\u00a0application\u00a0number\u00a0141-556.\u00a0<\/b>For\u00a0more\u00a0information,\u00a0see\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=2949195952&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin-CA1_Prescribing_Information.pdf&amp;a=full\" target=\"_blank\" rel=\"nofollow\">full<\/a><\/u>\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=1966285525&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin-CA1_Prescribing_Information.pdf&amp;a=prescribing+information\" target=\"_blank\" rel=\"nofollow\">prescribing information<\/a><\/u>\u00a0or visit <u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3681435076&amp;u=https%3A%2F%2Fbi-animalhealth.com%2Fpets%2Fcanine%2Fproducts%2Ftherapeutics%2Fvetmedin&amp;a=Vetmedinclinic.com\" target=\"_blank\" rel=\"nofollow\">Vetmedinclinic.com<\/a><\/u><\/p>\n<p><b>About\u00a0Boehringer Ingelheim<\/b><\/p>\n<p>Boehringer\u00a0Ingelheim is\u00a0a\u00a0biopharmaceutical\u00a0company\u00a0active in\u00a0both\u00a0human and\u00a0animal\u00a0health. As one of the industry&#8217;s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire\u00a0value chain. More\u00a0than\u00a053,500 employees\u00a0serve\u00a0over\u00a0130\u00a0markets\u00a0to\u00a0build a\u00a0healthier,\u00a0more sustainable, and equitable tomorrow. Lean more at boehringer-ingelheim.com\/us.<\/p>\n<p><b>About\u00a0Boehringer Ingelheim\u00a0\u2013\u00a0Animal\u00a0Health\u00a0business<\/b><\/p>\n<p>Boehringer Ingelheim provides first-in-class innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply\u00a0connected\u00a0and\u00a0strives\u00a0to\u00a0make\u00a0a\u00a0difference\u00a0for\u00a0people,\u00a0animals, and\u00a0society.\u00a0Learn\u00a0more\u00a0at boehringer-ingelheim.com\/animal-health.<\/p>\n<p><b>Media\u00a0Contact:<\/b><\/p>\n<p><span class=\"xn-person\">Chrissy Jones<\/span><br \/>Director, Corporate Affairs Boehringer Ingelheim\u00a0<br \/><u><a href=\"mailto:christine.jones@boehringer.com\" target=\"_blank\" rel=\"nofollow\">christine.jones@boehringer.com<\/a><\/u><\/p>\n<p>References<br \/><sup>1<\/sup>\u00a0Keene, Bruce W et al. &#8220;ACVIM consensus guidelines for the diagnosis and treatment of myxomatous\u00a0mitral\u00a0valve\u00a0disease in\u00a0dogs.&#8221;\u00a0<i>Journal\u00a0of\u00a0Veterinary\u00a0Internal Medicine\u00a0<\/i>vol.\u00a033,3\u00a0(2019): 1127-1140. doi:10.1111\/jvim.15488<br \/><sup>2<\/sup> H\u00e4ggstr\u00f6m,\u00a0J\u00a0et\u00a0al.\u00a0&#8220;Longitudinal\u00a0analysis\u00a0of\u00a0quality\u00a0of\u00a0life,\u00a0clinical,\u00a0radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving\u00a0pimobendan\u00a0or\u00a0benazepril:\u00a0the\u00a0QUEST\u00a0study.&#8221;\u00a0<i>Journal\u00a0of\u00a0Veterinary\u00a0Internal\u00a0Medicine\u00a0<\/i>vol. 27,6\u00a0(2013):\u00a01441-51. doi:10.1111\/jvim.12181<br \/><sup>3<\/sup>\u00a0Lombard, Christophe\u00a0W\u00a0et\u00a0al.\u00a0&#8220;Clinical\u00a0efficacy\u00a0of pimobendan\u00a0versus\u00a0benazepril\u00a0for\u00a0the\u00a0treatment of acquired atrioventricular valvular disease in dogs.&#8221; <i>Journal of the American Animal Hospital Association <\/i>vol. 42,4 (2006): 249-61. doi:10.5326\/0420249<br \/><sup>4<\/sup>\u00a0Epidemiologic simulation of Vetmedin usage 1999-2024, based on EPIC 2016 JVIM (MMVD, stage B2),\u00a0QUEST 2008\u00a0JVIM\u00a0(MMVD,\u00a0stage\u00a0C),\u00a0PROTECT 2012\u00a0JVIM\u00a0(DCM,\u00a0stage\u00a0B2),\u00a0O`Grady\u00a02008\u00a0JVIM<\/p>\n<p>(DCM,\u00a0stage\u00a0C),\u00a0Fuentes 2002\u00a0JVIM\u00a0(DCM\u00a0stage\u00a0C)\u00a0and\u00a0BI-owned sales\u00a0data.<\/p>\n<p>VETMEDIN<sup>\u00ae<\/sup>\u00a0is\u00a0a\u00a0registered\u00a0trademark\u00a0of\u00a0Boehringer\u00a0Ingelheim\u00a0Vetmedica\u00a0GmbH, used under license. \u00a92024 Boehringer\u00a0Ingelheim\u00a0Animal\u00a0Health\u00a0USA\u00a0Inc.,\u00a0Duluth, GA.\u00a0All\u00a0rights reserved.<\/p>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1 Previous studies have shown that\u00a0VETMEDIN\u00ae\u00a0could help\u00a0improve\u00a0the\u00a0survival\u00a0time\u00a0and quality\u00a0of\u00a0life\u00a0for\u00a0dogs\u00a0with\u00a0congestive\u00a0heart\u00a0failure\u00a0due\u00a0to\u00a0myxomatous\u00a0mitral\u00a0valve\u00a0disease (MMVD) or dilated cardiomyopathy (DCM)2,3 The new\u00a0VETMEDIN\u00ae\u00a0Solution\u00a0offers\u00a0pet\u00a0owners\u00a0a\u00a0convenient,\u00a0liquid\u00a0oral\u00a0treatment\u00a0option\u00a0for those dogs that prefer a liquid DULUTH, Ga, Nov. 23, 2024 \/PRNewswire\/ &#8212; Boehringer Ingelheim,\u00a0a\u00a0global leader\u00a0in\u00a0animal health, launched\u00a0VETMEDIN\u00ae\u00a0Solution, the [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61933","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs\" \/>\n<meta property=\"og:description\" content=\"Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1 Previous studies have show\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-23T00:04:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs\",\"datePublished\":\"2024-11-23T00:04:37+00:00\",\"dateModified\":\"2024-11-23T00:04:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/\"},\"wordCount\":1058,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/\",\"name\":\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-11-23T00:04:37+00:00\",\"dateModified\":\"2024-11-23T00:04:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs","og_description":"Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1 Previous studies have show","og_url":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-11-23T00:04:37+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs","datePublished":"2024-11-23T00:04:37+00:00","dateModified":"2024-11-23T00:04:37+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/"},"wordCount":1058,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/","url":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/","name":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-11-23T00:04:37+00:00","dateModified":"2024-11-23T00:04:37+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=61933"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61933\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=61933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=61933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=61933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}